Welcome to our dedicated page for CareDx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on CareDx stock.
CareDx, Inc. (NASDAQ: CDNA) is at the forefront of transforming transplant patient care through its innovative surveillance management solutions. Dedicated to improving the lives of organ transplant patients, CareDx leverages the latest in genomics and bioinformatics technology combined with rigorous clinical evidence derived from trials and registries.
CareDx offers a suite of precision medicine solutions aimed at enhancing both pre- and post-transplant care. One of its flagship products, AlloSure®, is the first and only non-invasive blood test that directly measures allograft injury. This next-generation sequencing (NGS) based test detects donor-derived cell-free DNA (dd-cfDNA), providing clinicians with a powerful tool to identify organ injury and the probability of active rejection, particularly in kidney transplant patients.
The company's portfolio also includes AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are dd-cfDNA solutions designed for heart and lung transplant recipients. These products underscore CareDx’s commitment to offering clinically differentiated, high-value healthcare solutions that span the entire transplant journey.
CareDx generates the majority of its revenue from the United States, with a significant portion coming from its testing services. Its product suite not only addresses the critical needs of transplant patients but also supports healthcare providers in delivering better patient outcomes through genomics-based information.
Recent achievements include the continued expansion of their product line and partnerships with leading healthcare institutions to further validate and implement their innovative diagnostic solutions. These efforts position CareDx as a leader in the field of transplant diagnostics and surveillance.
CareDx (CDNA), a precision medicine company specializing in transplant healthcare solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management team is scheduled to deliver a presentation on Tuesday, January 14, 2025, at 4:30 PM PT (7:30 PM ET).
Interested parties can access the webcast through the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. The company, which focuses on developing and commercializing high-value healthcare solutions for transplant patients and caregivers, continues to maintain its position as a leading force in transplant medicine.
TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies, announced a partnership with CareDx (NASDAQ: CDNA) to support the ACHIEVE clinical trial. This phase II, open-label study aims to evaluate the efficacy of TCB008, an allogeneic gamma delta T cell therapy for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
CareDx will use its AlloCell solution for pharmacokinetic analysis to monitor the expansion and persistence of TCB008 in patients. The data collected will help understand the duration and effect of TCB008 in reconstituting the immune system of AML patients. Alison Bracchi, EVP of Clinical Operations at TC BioPharm, highlighted the partnership as a significant milestone in developing TCB008. Marica Grskovic, PhD, CareDx Chief Strategy Officer, emphasized the collaboration's role in advancing allogeneic cell therapy for AML patients.
CareDx (CDNA) announces a partnership with TC BioPharm to provide pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE clinical trial. The phase II trial evaluates TCB008, an allogeneic gamma-delta T-cell therapy for patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). AlloCell, which has been used in ten previous cell therapy trials, will monitor the expansion and persistence of TCB008 in trial patients. This partnership aligns with CareDx's strategic expansion into hematology oncology, specifically focusing on pharmacokinetic and monitoring assays for cell therapy patients.
CareDx (Nasdaq: CDNA), a precision medicine company specializing in transplant healthcare solutions, has announced its participation in three upcoming investor conferences. The company will present at the Jefferies London Healthcare Conference on November 19 at 4:00 AM EST, the Stephens Investment Conference in Nashville on November 21 at 9:00 AM EST, and the Piper Sandler Healthcare Conference in New York on December 4 at 10:10 AM EST. Interested parties can access the webcasts through CareDx's Investor Relations website at investors.caredx.com.
CareDx reported strong Q3 2024 results with total revenue of $82.9 million, up 23% year-over-year. Testing Services volume increased 16% to 44,600 tests. While reporting a GAAP net loss of $7.4 million, the company achieved non-GAAP net income of $8.0 million and positive adjusted EBITDA of $6.9 million. Cash flow from operations was $12.5 million, with $241 million in cash and no debt. The company raised its 2024 revenue guidance to $327-331 million and adjusted EBITDA guidance to $18-22 million. CMS reaffirmed Medicare coverage for AlloSure® and AlloMap® testing, and surveillance testing mix in kidney showed improvement.
CareDx and Dovetail Genomics have announced a strategic partnership to advance HLA genotyping for organ and stem cell transplant matching. The collaboration combines CareDx's AlloSeq Tx 17, the first HLA typing solution covering 17 loci, with Dovetail's Hi-C LinkPrep technology to achieve high-resolution genotyping and haplotyping without family studies. The partnership includes an Early Access Program for HLA labs to evaluate innovative donor-recipient matching methods. The combined technology's performance will be presented at the 50th annual ASHI meeting.
CareDx, Inc. (Nasdaq: CDNA) announced new data and product enhancements at the 50th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in Anaheim, California. The company showcased advancements in its AlloSeq NGS-based HLA typing solutions for living organ donation and bone marrow transplantation. CareDx also launched an improved QTYPE solution with single bead antigen resolution for faster transplant decisions in deceased donor typing.
The company is hosting a symposium featuring Dr. Annette M. Jackson from Duke University, who will discuss findings on risk haplotypes in pediatric nephrotic syndrome. CareDx representatives will present innovations including a novel HLA haplotyping approach and QTYPE advancements. Key data presentations at ASHI 2024 will highlight the performance of AlloSeq Tx 11, buccal swab performance with AlloSeq Tx 17, and a new approach to HLA haplotyping using LinkPrep reagents with AlloSeq technology.
CareDx, Inc. (Nasdaq: CDNA) reported preliminary financial results for the third quarter of 2024. The company expects:
- Revenue between $82-83 million, up ~23% year-over-year
- Testing Services volume of ~44,600, up ~16% year-over-year
- Testing services revenue of $60-61 million, up ~26% year-over-year
- Patient and Digital Solutions revenue of ~$11.9 million, up 20% year-over-year
- Products revenue of ~$10.2 million, up 7% year-over-year
CareDx ended the quarter with ~$240 million in cash, cash equivalents, and marketable securities, with no debt. The company will report full Q3 2024 results on November 4, 2024, after market close, followed by a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
CareDx, Inc. (Nasdaq: CDNA), a precision medicine company focused on transplant healthcare solutions, has announced an inducement grant for its newly appointed Chief Data and AI Officer, Jing Huang. On October 8, 2024, Ms. Huang was granted 15,547 restricted stock units (RSUs) and an option to purchase 22,248 shares of CareDx common stock. The RSUs will vest over four years in equal annual installments starting October 8, 2025. The stock option, with an exercise price of $32.16, will vest over four years, with 25% vesting on October 8, 2025, and the remainder vesting monthly thereafter. This grant was made under CareDx's 2019 Inducement Equity Incentive Plan, approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on transplant healthcare solutions, has announced its upcoming Investor Day on October 15, 2024, in New York City. The event will begin at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time and will feature presentations from the company's leadership team.
Interested individuals can attend the event in person by registering online, but capacity is For those unable to attend, a live webcast will be available on the investor relations section of CareDx's website. A replay of the event will be posted on the company's website and will be accessible for at least 30 days after the event.
FAQ
What is the current stock price of CareDx (CDNA)?
What is the market cap of CareDx (CDNA)?
What does CareDx, Inc. specialize in?
What is AlloSure®?
Which organs do CareDx's products focus on?
Where does CareDx generate most of its revenue?
What are some key products offered by CareDx?
How does CareDx support transplant patients?
What technology does CareDx use in its diagnostics?
Does CareDx collaborate with other healthcare institutions?
What kind of clinical evidence does CareDx generate?
What makes CareDx a leader in transplant diagnostics?
